Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
Moritz von FalloisFriederike Katharina KosynaMarkus MandlYosef LandesmanJürgen DunstReinhard DeppingPublished in: Journal of cancer research and clinical oncology (2021)
Targeting the HIF pathway by Selinexor might be an attractive tool to overcome hypoxia-induced radioresistance.